Comparison of benazepril plus amlodipine or hydrochlorothiazide in high-risk patients with hypertension and coronary artery disease

G Bakris, A Briasoulis, B Dahlof, K Jamerson… - The American journal of …, 2013 - Elsevier
Combination therapy with benazepril 40 mg and amlodipine 10 mg (B+ A) has been shown
to be more effective than benazepril 40 mg and hydrochlorothiazide (HCTZ) 25 mg (B+ H) in …

Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients

K Jamerson, MA Weber, GL Bakris… - … England Journal of …, 2008 - Mass Medical Soc
Background The optimal combination drug therapy for hypertension is not established,
although current US guidelines recommend inclusion of a diuretic. We hypothesized that …

The Avoiding Cardiovascular events through COMbination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: a comparison of first-line …

AB Weder - Expert Opinion on Pharmacotherapy, 2005 - Taylor & Francis
Although multidrug therapy is required in order to achieve good blood pressure control in
many hypertensives, there are no studies directly comparing fixed-dose combinations as …

Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: a …

MA Weber, GL Bakris, B Dahlöf, B Pitt… - Blood …, 2007 - Taylor & Francis
ACCOMPLISH is the first trial designed to compare the effects on major fatal and non‐fatal
cardiovascular endpoints of two forms of antihypertensive combination therapy: benazepril …

Efficacy and duration of benazepril plus amlodipine or hydrochlorthiazide on 24-hour ambulatory systolic blood pressure control

KA Jamerson, R Devereux, GL Bakris, B Dahlöf… - …, 2011 - Am Heart Assoc
The combination of benazepril plus amlodipine was shown to be more effective than
benazepril plus hydrochlorothiazide in reducing cardiovascular events in the Avoiding …

Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial: the first …

KA Jamerson, GL Bakris, CC Wun… - American journal of …, 2004 - academic.oup.com
Reducing blood pressure (BP) to target levels is a major priority in preventing clinical events
in hypertension. Typically this requires more than one drug, and recent guidelines on …

Amlodipine/benazepril combination therapy for hypertensive patients nonresponsive to benazepril monotherapy

SG Chrysant, GL Bakris - American journal of hypertension, 2004 - academic.oup.com
Background: Most patients with hypertension require two or more antihypertensive
medications to achieve blood pressure (BP) goals. This double-blind study compared the …

The diabetes subgroup baseline characteristics of the Avoiding Cardiovascular Events through Combination Therapy in Patients Living with Systolic Hypertension …

G Bakris, A Hester, M Weber, B Dahlof… - Journal of the …, 2008 - Wiley Online Library
The Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With
Systolic Hypertension (ACCOMPLISH) trial is the first cardiovascular outcome trial designed …

Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified …

GL Bakris, PA Sarafidis, MR Weir, B Dahlöf, B Pitt… - The Lancet, 2010 - thelancet.com
Summary Background The Avoiding Cardiovascular Events through Combination Therapy
in Patients Living with Systolic Hypertension (ACCOMPLISH) trial showed that initial …

Cardiovascular events during differing hypertension therapies in patients with diabetes

MA Weber, GL Bakris, K Jamerson, M Weir… - Journal of the American …, 2010 - jacc.org
Objectives: The aim of this study was to determine which combination therapy in patients
with hypertension and diabetes most effectively decreases cardiovascular events …